https://minervaneurosciences.com/resource/efficacy-and-safety-of-roluperidone-for-the-treatment-of-negative-symptoms-of-schizophrenia/ 2026-06-29T15:05:44+00:00 https://minervaneurosciences.com/resource/efficacy-and-safety-of-min-101-a-12-week-randomized-double-blind-placebo-controlled-trial-of-a-new-drug-in-development-for-the-treatment-of-negative-symptoms-in-schizophrenia/ 2026-06-29T15:06:16+00:00 https://minervaneurosciences.com/resource/the-brief-negative-symptom-scale-bnss-sensitivity-to-treatment-effects/ 2026-06-29T15:07:32+00:00 https://minervaneurosciences.com/resource/cognitive-effects-of-min-101-in-patients-with-schizophrenia-and-negative-symptoms-results-from-a-randomized-controlled-trial/ 2026-06-29T15:07:44+00:00 https://minervaneurosciences.com/resource/letter-to-the-editor-personal-and-social-adjustment-effects-of-roluperidone-in-patients-with-schizophrenia-and-negative-symptoms-results-from-an-exploratory-outcome-of-a-randomized-placebo-controlle/ 2026-06-29T15:07:55+00:00 https://minervaneurosciences.com/resource/effects-of-roluperidone-min-101-on-two-dimensions-of-the-negative-symptoms-factor-score-reduced-emotional-experience-and-reduced-emotional-expression/ 2026-06-29T15:08:02+00:00 https://minervaneurosciences.com/resource/network-analysis-indicates-that-avolition-is-the-most-central-domain-for-the-successful-treatment-of-negative-symptoms-evidence-from-the-roluperidone-randomized-clinical-trial/ 2026-06-29T15:08:09+00:00